Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor

Journal of Cellular Physiology

Volumn 204, Issue 2, 2005, Pages 714-723

  Zannettino, A C W ^a   Holding, C A ^b   Diamond, P ^a   Atkins, G J ^b   Kostakis, P ^a   Farrugia, A ^a   Gamble, J ^a   To, L B ^a   Findlay, D M ^b   Haynes, D R ^b  

^a HANSON INSTITUTE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; OSTEOPROTEGERIN; PADGEM PROTEIN; THROMBOSPONDIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR REDUCTASE;

ARTERY CALCIFICATION; ARTICLE; BLOOD VESSEL INJURY; BONE TISSUE; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOTHELIUM CELL; HEMOSTASIS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INFLAMMATION; OSTEOCLAST; PERIPHERAL CIRCULATION; PLASMA; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; VASCULAR ENDOTHELIUM; WEIBEL PALADE BODY;

CARRIER PROTEINS; CELLS, CULTURED; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; THROMBOSPONDIN 1; TIME FACTORS; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA; VON WILLEBRAND FACTOR; WEIBEL-PALADE BODIES;

EID: 21644448012     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20354     Document Type: Article

References (73)

1. Arnaout MA. 1993. Cell adhesion molecules in inflammation and thrombosis: Status and prospects. Am J Kidney Dis 21(1):72-76.
2. Bateman TA, Dunstan CR, Lacey DL, Ferguson VL, Ayers RA, Simske SJ. 2001. Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. J Orthop Res 19(4):518-523.
3. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. 2004. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultra-large von Willebrand factor multimers under flow. Blood.
4. Bonfanti R, Furie BC, Furie B, Wagner DD. 1989. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 73(5):1109-1112.
5. Bostrom K, Demer LL. 2000. Regulatory mechanisms in vascular calcification. Crit Rev Eukaryot Gene Expr 10(2):151-158.
6. Brandstrom H, Jonsson KB, Ohlsson C, Vidal O, Ljunghall S, Ljunggren O. 1998a. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. Biochem Biophys Res Commun 247(2):338-341.
7. Brandstrom H, Jonsson KB, Vidal O, Ljunghall S, Ohlsson C, Ljunggren O. 1998b. Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun 248(3):454-457.
8. Browner WS, Lui LY, Cummings SR. 2001. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86(2):631-637.
9. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. 1998. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12(9):1260-1268.
10. Chagraoui H, Sabri S, Capron C, Villeval JL, Vainchenker W, Wendling F. 2003. Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. Exp Hematol 31(11):1081-1088.
11. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. 2001. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276(23):20659-20672.
12. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA. 2002. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100(12):4033-4039.
13. Emanuele E, Peros E, Scioli GA, D'Angelo A, Olivieri C, Montagna L, Geroldi D. 2004. Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease. Int J Mol Med 13(6):849-853.
14. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273(23):14363-14367.
15. Feige U, Hu YL, Gasser J, Campagnuolo G, Munyakazi L, Bolon B. 2000. Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci 57(10):1457-1470.
16. Feuerherm AJ, Borset M, Seidel C, Sundan A, Leistad L, Ostensen M, Faxvaag A. 2001. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol 30(4):229-234.
17. Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. 1985. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 82(24):8667-8671.
18. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. 2001. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98(13):3527-3533.
19. Golledge J, McCann M, Mangan S, Lam A, Karan M. 2004. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35(7):1636-1641.
20. Hattori R, Hamilton KK, McEver RP, Sims PJ. 1989. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 264(15):9053-9060.
21. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. 2001. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxf) 40(6):623-630.
22. Haynes DR, Barg E, Crotti T, Weedon H, Atkins GJ, Zannettino ACW, Ahern MJ, Coleman M, Roberts-Thomson PJ, Kraan M, Tak PP, Smith MD. 2003. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxf) 42(1):123-134.
23. Hofbauer LC, Heufelder AE. 2001. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79(5-6): 243-253.
24. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. 1998. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 250(3):776-781.
25. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. 1999. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25(3):255-259.
26. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. 2000. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15(1):2-12.
27. Hogg PJ, Stenflo J, Mosher DF. 1992. Thrombospondin is a slow tight-binding inhibitor of plasmin. Biochemistry 31(1):265-269.
28. Hogg PJ, Owensby DA, Chesterman CN. 1993a. Thrombospondin 1 is a tight-binding competitive inhibitor of neutrophil cathepsin G. Determination of the kinetic mechanism of inhibition and localization of cathepsin G binding to the thrombospondin 1 type 3 repeats. J Biol Chem 268(29):21811-21818.
29. Hogg PJ, Owensby DA, Mosher DF, Misenheimer TM, Chesterman CN. 1993b. Thrombospondin is a tight-binding competitive inhibitor of neutrophilelastase. J Biol Chem 268(10):7139-7146.
30. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. 1998. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139(11):4743-4746.
31. Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT. 1999. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 265(1):144-150.
32. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. 1999. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96(7):3540-3545.
33. Jilma B, Fasching P, Ruthner C, Rumplmayr A, Ruzicka S, Kapiotis S, Wagner OF, Eichler HG. 1996. Elevated circulating P-selectin in insulin dependent diabetes mellitus. Thromb Haemost 76(3):328-332.
34. Kaden JJ, Bickelhaupt S, Grobholz R, Haase KK, Sarikoc A, Kilic R, Brueckmann M, Lang S, Zahn I, Vahl C, Hagl S, Dempfle CE, Borggrefe M. 2004. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36(1):57-66.
35. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. 2004. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109(18): 2175-2180.
36. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Takahashi K, Furuya T, Ishiyama S, Kim KJ, Saito S, Nishikawa T, Takahashi N, Togari A, Tomatsu T, Suda T, Kamatani N. 2001. Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44(5):1003-1012.
37. Kraan MC, Haringman JJ, Ahern MJ, Breedveld FC, Smith MD, Tak PP. 2000. Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxf) 39(1):43-49.
38. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2):165-176.
39. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(259):680-685.
40. Lee SK, Lorenzo JA. 1999. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 140(8):3552-3561.
41. Littler AJ, Buckley CD, Wordsworth P, Collins I, Martinson J, Simmons DL. 1997. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol 36(2):164-169.
42. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. 2000. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 275(28):20959-20962.
43. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. 2000. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192(4):463-474.
44. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H. 1998. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247(3):610-615.
45. Molostvov G, Morris A, Rose P, Basu S. 2001. Interaction of cytokines and growth factor in the regulation of verotoxin-induced apoptosis in cultured human endothelial cells. Br J Haematol 113(4):891-897.
46. Mosher DF, Misenheimer TM, Stenflo J, Hogg PJ. 1992. Modulation of fibrinolysis by thrombospondin. Ann NY Acad Sci 667:64-69.
47. Mukohyama H, Ransjo M, Taniguchi H, Ohyama T, Lerner UH. 2000. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. Biochem Biophys Res Commun 271(1):158-163.
48. Nitta K, Akiba T, Uchida K, Otsubo S, Takei T, Yumura W, Kabaya T, Nihei H. 2004. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrology Dialysis Transplantation 19(7):1886-1889.
49. O'Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. 1999. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 274(27):19301-19308.
50. Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, McClure D, Seno G, Churgay L, Chandrasekhar S, Martin TJ. 2000. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 15(5):863-871.
51. Padilla A, Moake JL, Bernardo A, Ball C, Wang Y, Arya M, Nolasco L, Turner N, Berndt MC, Anvari B, Lopez JA, Dong JF. 2004. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 103(6):2150-2156.
52. Parker A, Smith MD. 1999. Immunohistochemical detection of cytokines and cell adhesion molecules in the synovial membrane. Methods Find Exp Clin Pharmacol 21(5):311-319.
53. Pimanda JE, Ganderton T, Maekawa A, Yap CL, Lawler J, Kershaw G, Chesterman CN, Hogg PJ. 2004. Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice. J Biol Chem 279(20):21439-21448.
54. Pritzker LB, Scatena M, Giachelli CM. 2004. The role of osteoprotegerin and Tnf-related apoptosis inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 15:2834-2841.
55. Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF, Martin TJ, Gillespie MT. 2000. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 43(4:821-826.
56. Sambrook J FE, Maniatis T. 1989. Molecular cloning: A laboratory manual, 2nd edition. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
57. Schoppet M, Al-Fakhri N, Franke FE, Katz N, Earth PJ, Maisch B, Preissner KT, Hofbauer LC. 2004. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-{kappa}B ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 89(8):4104-4112.
58. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. 1997. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89(2):309-319.
59. Takahashi N, Udagawa N, Suda T. 1999. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 256(3):449-455.
60. Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K, Watanabe K, Yamada Y. 1998. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 273(42):27091-27096.
61. Ueda H, Doi Y, Sakamoto Y, Hamasaki K, Fujimoto S. 1992. Simultaneous localization of histamine and factor VIII-related antigen in the endothelium of the human umbilical vein. Anat Rec 232(2):257-261.
62. Vidal NO, Brandstrom H, Jonsson KB, Ohlsson C. 1998. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids. J Endocrinol 159(1):191-195.
63. Vischer UM, Wagner DD. 1994. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood 83(12):3536-3544.
64. Wagner DD. 1990. Cell biology of von Willebrand factor. Annu Rev Cell Biol 6:217-246.
65. Wagner DD. 1993. The Weibel-Palade body: The storage granule for von Willebrand factor and P-selectin. Thromb Haemost 70(1):105-110.
66. Wagner DD, Olmsted JB, Marder VJ. 1982. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 95(1):355-360.
67. Wallin R, Wajih N, Greenwood GT, Sane DC. 2001. Arterial calcification: A review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 21(4):274-301.
68. Xie L, Chesterman CN, Hogg PJ. 2001. Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med 193(12):1341-1349.
69. Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, Higashio K. 1998. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 273(9):5117-5123.
70. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K. 1998. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139(3):1329-1337.
71. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, Mochizuki SI, Tsuda E, Morinaga T, Udagawa N, Takahashi N, Suda T, Higashio K. 1999. A novel molecular mechanism modulating osteoclast differentiation and function. Bone 25(1):109-113.
72. Yun TJ, Tallquist MD, Aicher A, Rafferty KL, Marshall AJ, Moon JJ, Ewings ME, Mohaupt M, Herring SW, Clark EA. 2001. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 166(3):1482-1491.
73. Zannettino AC, Rayner JR, Ashman LK, Gonda TJ, Simmons PJ. 1996. A powerful new technique for isolating genes encoding cell surface antigens using retroviral expression cloning. J Immunol 156(2):611-620.